Top Australian Biotech Company CSL Enters Race to Find Coronavirus Vaccine
Australia’s largest biotech firm CSL stated Wednesday it should start trials for an antibody product to treat people with the novel coronavirus, becoming a member of a global rush to find a treatment for a fast-spreading and potentially deadly illness.
CSL mentioned in a statement it should test a blood plasma treatment for folks with critical cases of the sickness, formally called COVID-19, by gathering blood from people who have recovered from it and concentrating their virus-fighting antibodies.
The trial puts Australia’s second most precious firm in the race to discover a treatment for the sickness for which there is still no verified vaccine or treatment. Almost 3.7 million people have caught the flu-like sickness since it was first reported in China in late 2019, of whom practically 260,000 have died.
Australian well-being minister Greg Hunt stated in the assertion the CSL facility could be one of the first on the planet to start the development of an immunoglobulin, which will provide profit to seriously ill Australians in need of treatment.
Immunoglobulin refers to virus-fighting antibodies typically discovered in the blood cells of people who have recovered from a virus.
CSL, which began as a government laboratory called Commonwealth Serum Laboratories before it was privatized, said it would need blood plasma donations from nearly 800 people, collected by the Australian Red Cross, to produce sufficient immunoglobulin to treat between 50 and 100 severely ill patients under the trial.
Australia had posted nearly 6,900 infections of the coronavirus, along with 97 deaths, by Wednesday, based on government figures.